PPCB (NASDAQ:PPCB – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share for the quarter, FiscalAI reports.
PPCB Trading Down 1.5%
Shares of NASDAQ PPCB traded down $0.00 during midday trading on Thursday, reaching $0.21. The company had a trading volume of 163,436 shares, compared to its average volume of 2,101,146. PPCB has a one year low of $0.16 and a one year high of $11.00. The firm has a market cap of $3.12 million, a PE ratio of 0.00 and a beta of 3.66.
Analyst Ratings Changes
Separately, Weiss Ratings began coverage on PPCB in a research report on Wednesday, January 14th. They set a “sell (e-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.
PPCB Company Profile
Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.
Featured Articles
- Five stocks we like better than PPCB
- Your Bank Account Is No Longer Safe
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for PPCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPCB and related companies with MarketBeat.com's FREE daily email newsletter.
